The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2021 | Novel therapies in low-risk MDS
Valeria Santini, MD, University of Florence, Florence, Italy, outlines the novel therapies for the treatment of low-risk myelodysplastic syndromes (MDS), highlighting clinical data from key trials. Specifically discussed is luspatercept, a fusion ligand trap agent for activin II receptor and B, imetelstat, a first-in-class oligonucleotide and roxadustat, a potent and reversible orally bioavailable small-molecule inhibitor of HIF-PH enzymes. This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.
